SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 194 filers reported holding SAGE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $249,579 | -46.1% | 12,129 | +23.3% | 0.00% | -100.0% |
| Q2 2023 | $462,640 | -17.5% | 9,840 | -26.3% | 0.00% | 0.0% |
| Q1 2023 | $560,543 | +6.2% | 13,360 | -3.3% | 0.00% | 0.0% |
| Q4 2022 | $528,000 | -1.5% | 13,823 | +1.1% | 0.00% | 0.0% |
| Q3 2022 | $536,000 | +19.9% | 13,673 | -1.0% | 0.00% | 0.0% |
| Q2 2022 | $447,000 | +18.3% | 13,814 | +21.1% | 0.00% | 0.0% |
| Q1 2022 | $378,000 | +27.7% | 11,406 | +63.6% | 0.00% | 0.0% |
| Q4 2021 | $296,000 | +166.7% | 6,974 | +175.7% | 0.00% | – |
| Q3 2021 | $111,000 | -78.9% | 2,530 | -72.5% | 0.00% | -100.0% |
| Q2 2021 | $527,000 | +621.9% | 9,211 | +852.5% | 0.00% | – |
| Q1 2021 | $73,000 | -26.3% | 967 | -15.2% | 0.00% | – |
| Q4 2020 | $99,000 | +219.4% | 1,141 | +121.1% | 0.00% | – |
| Q3 2020 | $31,000 | -3.1% | 516 | -35.3% | 0.00% | – |
| Q2 2020 | $32,000 | +28.0% | 798 | -10.6% | 0.00% | – |
| Q1 2020 | $25,000 | – | 893 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sio Capital Management, LLC | 179,200 | $29,516,000 | 16.65% |
| TRV GP II, LLC | 547,916 | $90,247,000 | 16.25% |
| Opus Point Partners Management, LLC | 71,000 | $11,694,000 | 10.12% |
| Casdin Capital, LLC | 250,000 | $41,178,000 | 10.03% |
| RA Capital Management | 455,173 | $74,972,000 | 6.27% |
| Crawford Lake Capital Management, LLC | 154,278 | $25,411,000 | 6.00% |
| Palo Alto Investors LP | 810,806 | $133,548,000 | 5.75% |
| GREAT POINT PARTNERS LLC | 200,000 | $32,942,000 | 5.62% |
| BB BIOTECH AG | 1,042,439 | $171,700,000 | 4.84% |
| Crawford Lake Capital Management, LLC | 92,300 | $15,203,000 | 3.59% |